https://pharminent.com/market-access/market-access-intelligence-midweek-update-april-29-2026/ 2026-04-30T12:40:17Z Pharminent en Market Access Intelligence • Midweek Update • April 29, 2026 2026-04-30T12:40:14Z Blog https://pharminent.com/lilly-clocks-56-revenue-increase-in-q1-but-declining-prices-stunt-growth/ 2026-04-30T13:23:50Z Pharminent en Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth 2026-04-30T12:07:45Z Blog https://pharminent.com/teva-makes-its-first-ma-play-in-years-buying-emalex/ 2026-04-30T13:23:12Z Pharminent en Teva makes its first M&A play in years, buying Emalex 2026-04-30T11:50:14Z Blog https://pharminent.com/astrazeneca-prunes-asthma-rare-disease-pipeline-cultivates-cancer-portfolio/ 2026-04-30T13:27:21Z Pharminent en AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio 2026-04-30T11:41:20Z Blog https://pharminent.com/gsk-partnered-alector-hit-with-third-neuro-failure-as-alzheimers-asset-disappoints/ 2026-04-30T13:24:22Z Pharminent en GSK-partnered Alector hit with third neuro failure as Alzheimer's asset disappoints 2026-04-30T11:27:58Z Blog https://pharminent.com/norgine-gets-first-eu-approval-for-whim-syndrome-therapy/ 2026-04-30T13:20:39Z Pharminent en Norgine gets first EU approval for WHIM syndrome therapy 2026-04-30T09:36:27Z Blog https://pharminent.com/regeneron-q1-2026-net-income-falls-10-to-727m/ 2026-04-30T13:19:51Z Pharminent en Regeneron Q1 2026 net income falls 10% to $727m 2026-04-30T09:22:58Z Blog https://pharminent.com/ray-therapeutics-receives-ema-prime-status-for-gene-therapy-2/ 2026-04-30T13:10:58Z Pharminent en Ray Therapeutics receives EMA PRIME status for gene therapy 2026-04-30T09:21:15Z Blog https://pharminent.com/survodutide-delivers-16-6-weight-loss-in-major-phase-3-obesity-trial/ 2026-04-30T13:19:23Z Pharminent en Survodutide delivers 16.6% weight loss in major phase 3 obesity trial 2026-04-30T09:08:40Z Blog https://pharminent.com/avalyn-in-pursuit-of-better-lung-drugs-banks-300m-in-an-ipo/ 2026-04-30T13:10:48Z Pharminent en Avalyn, in pursuit of better lung drugs, banks $300M in an IPO 2026-04-30T01:06:00Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-april-29-2026/ 2026-04-29T23:46:08Z Pharminent en Manufacturing Intelligence • Weekly Digest • April 29, 2026 2026-04-29T23:46:04Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-april-29-2026/ 2026-04-29T22:56:42Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • April 29, 2026 2026-04-29T22:56:38Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-april-29-2026/ 2026-04-29T18:39:31Z Pharminent en Strategic News Watch • April 29, 2026 2026-04-29T18:39:28Z Blog https://pharminent.com/pfizer-protects-6-4bn-heart-disease-blockbuster-from-generics-for-now/ 2026-04-30T13:09:43Z Pharminent en Pfizer protects $6.4bn heart disease blockbuster from generics, for now 2026-04-29T15:59:24Z Blog https://pharminent.com/chiesi-to-buy-kalvista-in-1-9b-deal-for-rare-disease-drug/ 2026-04-30T13:28:49Z Pharminent en Chiesi to buy KalVista in $1.9B deal for rare disease drug 2026-04-29T15:34:00Z Blog https://pharminent.com/fda-tests-out-real-time-clinical-trials-abbvie-closes-in-on-a-kras-biotech/ 2026-04-30T13:08:17Z Pharminent en FDA tests out 'real-time' clinical trials; AbbVie closes in on a KRAS biotech 2026-04-29T15:21:00Z Blog https://pharminent.com/flash-brief-pbm-reform-collides-with-mfn-pricing-as-midterm-politics-reshape-the-drug-pricing-landscape/ 2026-04-30T12:46:35Z Pharminent en Flash Brief: PBM Reform Collides with MFN Pricing as Midterm Politics Reshape the Drug Pricing Landscape 2026-04-29T12:43:47Z Blog https://pharminent.com/pfizer-settles-with-generic-drugmakers-to-protect-blockbuster-drug-until-2031/ 2026-04-29T12:43:34Z Pharminent en Pfizer settles with generic drugmakers to protect blockbuster drug until 2031 2026-04-29T12:15:28Z Blog https://pharminent.com/az-amgen-will-pilot-fdas-real-time-clinical-trial-plan/ 2026-04-29T12:41:39Z Pharminent en AZ, Amgen will pilot FDA's real-time clinical trial plan 2026-04-29T12:03:58Z Blog https://pharminent.com/astrazeneca-faces-uphill-battle-at-upcoming-adcomm-in-face-of-fda-questions/ 2026-04-29T12:43:44Z Pharminent en AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions 2026-04-29T11:27:30Z Blog https://pharminent.com/generic-of-novos-glp-1-arrives-in-canada-a-test-case-for-the-world/ 2026-04-29T12:44:43Z Pharminent en Generic of Novo's GLP-1 arrives in Canada, a 'test case for the world' 2026-04-29T11:26:27Z Blog https://pharminent.com/eli-lilly-bets-on-recombinases-in-2-25bn-profluent-rd-pact/ 2026-04-29T12:44:54Z Pharminent en Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact 2026-04-29T10:51:54Z Blog https://pharminent.com/the-strategic-investments-expanding-cdmo-capabilities-for-hpapis-and-adcs/ 2026-04-29T12:36:16Z Pharminent en The strategic investments expanding CDMO capabilities for HPAPIs and ADCs 2026-04-29T10:42:51Z Blog https://pharminent.com/novartis-q1-sales-miss-hints-at-industrys-utilisation-of-ma-remedies/ 2026-04-29T12:37:34Z Pharminent en Novartis' Q1 sales miss hints at industry's utilisation of M&A remedies 2026-04-29T10:18:12Z Blog https://pharminent.com/arcera-and-fosun-sign-mou-for-neuroscience-innovation/ 2026-04-29T12:37:34Z Pharminent en Arcera and Fosun sign MoU for neuroscience innovation 2026-04-29T10:11:27Z Blog https://pharminent.com/rocket-to-sell-prv-for-180m-to-advance-gene-therapy-pipeline/ 2026-04-29T12:37:34Z Pharminent en Rocket to sell PRV for $180m to advance gene therapy pipeline 2026-04-29T09:55:00Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-april-28-2026/ 2026-04-28T22:54:40Z Pharminent en Oncology Intelligence Digest • April 28, 2026 2026-04-28T22:54:36Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-april-28-2026/ 2026-04-28T16:58:27Z Pharminent en Strategic News Watch • April 28, 2026 2026-04-28T16:58:23Z Blog https://pharminent.com/pfizer-deals-extend-patent-life-for-a-top-selling-rare-disease-drug/ 2026-04-29T12:45:34Z Pharminent en Pfizer deals extend patent life for a top-selling rare disease drug 2026-04-28T16:28:00Z Blog https://pharminent.com/intellia-initiates-rolling-bla-submission-for-in-vivo-crispr-therapy-in-hereditary-angioedema/ 2026-04-29T12:40:06Z Pharminent en Intellia Initiates Rolling BLA Submission for In Vivo CRISPR Therapy in Hereditary Angioedema 2026-04-28T14:42:03Z Blog https://pharminent.com/abbvie-sinks-talons-into-kras-with-right-to-buy-kestrel-for-up-to-1-45b/ 2026-04-29T12:29:22Z Pharminent en AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B 2026-04-28T14:27:49Z Blog https://pharminent.com/boehringer-zealands-obesity-drug-more-akin-to-novos-wegovy-in-phase-3/ 2026-04-28T15:42:30Z Pharminent en Boehringer, Zealand's obesity drug 'more akin' to Novo's Wegovy in Phase 3 2026-04-28T14:23:20Z Blog https://pharminent.com/aacr-2026-combo-therapies-by-moderna-marengo-show-promise-in-skin-breast-cancer/ 2026-04-28T15:42:34Z Pharminent en AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer 2026-04-28T14:19:24Z Blog https://pharminent.com/lilly-ai-biotech-profluent-ink-2-25b-pact-in-search-of-genetic-medicine-holy-grail/ 2026-04-28T15:42:38Z Pharminent en Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine 'holy grail' 2026-04-28T13:30:53Z Blog https://pharminent.com/coultreon-banks-125m-to-support-testing-of-former-galapagos-immune-drug/ 2026-04-29T12:29:25Z Pharminent en Coultreon banks $125M to support testing of former Galapagos immune drug 2026-04-28T12:33:00Z Blog https://pharminent.com/gsk-eyes-october-fda-verdict-on-chronic-hep-b-drug/ 2026-04-28T15:42:41Z Pharminent en GSK eyes October FDA verdict on chronic hep B drug 2026-04-28T11:39:43Z Blog https://pharminent.com/merck-kgaa-and-remepy-join-forces-to-develop-combo-drug-digital-therapies/ 2026-04-29T12:29:27Z Pharminent en Merck KGaA and Remepy join forces to develop combo drug-digital therapies 2026-04-28T11:00:25Z Blog https://pharminent.com/novartis-shares-fall-as-entresto-sales-weaken/ 2026-04-28T15:42:43Z Pharminent en Novartis shares fall as Entresto sales weaken 2026-04-28T10:24:18Z Blog https://pharminent.com/seaport-and-hemab-target-180m-ipos-as-biotech-listings-accumulate/ 2026-04-28T15:42:46Z Pharminent en Seaport and Hemab target $180m IPOs as biotech listings accumulate 2026-04-28T10:22:38Z Blog https://pharminent.com/boehringer-zealand-dual-acting-drug-causes-16-6-weight-loss/ 2026-04-28T15:42:47Z Pharminent en Boehringer/Zealand dual-acting drug causes 16.6% weight loss 2026-04-28T09:26:41Z Blog https://pharminent.com/biomarin-acquires-amicus-therapeutics-for-4-8bn-2/ 2026-04-28T15:42:48Z Pharminent en BioMarin acquires Amicus Therapeutics for $4.8bn 2026-04-28T08:51:54Z Blog https://pharminent.com/fda-approves-astrazenecas-saphnelo-for-sle-2/ 2026-04-28T15:22:45Z Pharminent en FDA approves AstraZeneca's Saphnelo for SLE 2026-04-28T08:25:11Z Blog